F5 (FFIV) Form 144 Filed for 2,701-Share Sale on NASDAQ
Rhea-AI Filing Summary
Form 144 filed for F5, Inc. (FFIV) shows a proposed sale of 2,701 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $855,055.57. The filing lists three tranches of restricted stock acquired from the issuer on 02/01/2025 (200 shares), 05/01/2025 (2,291 shares), and 08/01/2025 (210 shares), all paid on their acquisition dates. No securities were reported sold in the prior three months. The filer certifies they are not aware of undisclosed material adverse information. The notice documents the intent to sell shares by an individual for whose account the securities were issued and identifies the executing broker and approximate sale date of 09/08/2025.
Positive
- Disclosure complies with Rule 144 requirements, listing broker, share counts, acquisition dates, and aggregate market value
- No sales by the account in the prior three months, reducing concerns about rapid disposition patterns
Negative
- None.
Insights
TL;DR Insider plans to sell 2,701 restricted shares worth $855k via Morgan Stanley; transaction appears routine and disclosed under Rule 144.
The filing specifies the sale of restricted common stock granted by the issuer across three grant dates in 2025, aggregated for Rule 144 reporting. The aggregate size relative to typical institutional or company float is not provided, so materiality to FFIV's market capitalization cannot be assessed from this form alone. The lack of sales in the prior three months suggests this is not part of an ongoing rapid disposition pattern. The scheduled trade date is listed as 09/08/2025 and the broker is a major dealer, indicating a standard market-channel disposition.
TL;DR Transaction conforms to Rule 144 mechanics; disclosures are routine and include required signer representation about material nonpublic information.
The form documents acquisition as restricted stock from the issuer and includes the required representation regarding absence of undisclosed material adverse information. There is no indication of a trading plan date or Rule 10b5-1 adoption in the remarks, and the filing shows no recent sales to aggregate. From a governance perspective, the form meets Rule 144 disclosure elements but does not provide context on why the sale is occurring or its relation to any executive role or plan.
FAQ
What does the Form 144 filed for FFIV disclose?
When were the shares being sold acquired?
Does the filing report any securities sold in the past three months?
Who is the executing broker listed on the Form 144?
Does the filing indicate the seller has material nonpublic information?